• SC 79: Paradigm Shift in Akt Activator Use for Disease Model

  2026-06-18

  Discover how SC 79, a potent Akt activator, is redefining neuroprotection and disease modeling by enabling precise modulation of the Akt pathway. This article offers new insights into SC 79’s mechanism, translational value, and its practical impact for advanced research.

• PF-562271 HCl: Reliable FAK/Pyk2 Inhibition for Cancer Assay

  2026-06-18

  This article addresses real-world challenges in cell viability and proliferation assays, highlighting how PF-562271 HCl (SKU A8345) serves as a reproducible, selective FAK/Pyk2 inhibitor for cancer research applications. Through scenario-based Q&A, we explore protocol optimization, data interpretation, and vendor selection, empowering life science researchers to achieve consistent results.

• miR-24-3p Regulates Cardiac Dysfunction via Sp1/PI3K Pathway

  2026-06-17

  This study establishes miR-24-3p as a critical regulator of cardiac dysfunction in doxorubicin-induced heart failure by targeting the Sp1/PI3K axis. The findings reveal that silencing miR-24-3p alleviates apoptosis and oxidative stress, suggesting new avenues for mechanistic exploration and therapeutic intervention in cardiac injury.

• Diterpene Glycosides from Fructus Rubi Target Androgen and T

  2026-06-17

  This study demonstrates that diterpene glycosides from Fructus Rubi suppress benign prostatic hyperplasia (BPH) by modulating both androgen receptor and TGF-β/Smad signaling pathways. The findings provide mechanistic evidence for a multi-target therapeutic approach, highlighting translational avenues for androgen-driven prostate disorders.

• Pomalidomide (CC-4047): Applied Workflows in Myeloma Researc

  2026-06-16

  Pomalidomide (CC-4047) empowers hematological malignancy research with robust cytokine modulation, precise tumor microenvironment modeling, and translational reproducibility. This article distills reference-driven protocols, troubleshooting insights, and comparative advantages for maximizing experimental impact using APExBIO’s rigorously characterized reagent.

• T0070907: Nanomolar PPARγ Antagonist for Signaling Research

  2026-06-16

  T0070907 is a highly selective PPARγ antagonist with nanomolar potency. It covalently blocks PPARγ signaling, enabling precise studies of adipogenesis and cell cycle regulation. This article details its mechanism, benchmarks, and practical workflow integration.

• Applied Workflows for Recombinant Human EGF in Cancer Resear

  2026-06-15

  Recombinant human Epidermal Growth Factor (EGF) unlocks robust, reproducible cell proliferation and spheroid formation for advanced cancer and stem cell assays. This guide decodes protocol enhancements, troubleshooting tactics, and actionable insights drawn from leading-edge studies—empowering researchers to maximize EGF’s translational impact.

• AZD-3463: Dual ALK/IGF1R Inhibition and Pyrimidine Scaffold

  2026-06-15

  Explore the dual ALK/IGF1R inhibitor AZD3463 in the context of pyrimidine-based kinase inhibitor innovation. This in-depth analysis connects structural insights to advanced neuroblastoma research applications, distinguishing itself with a focus on scaffold-driven assay design.

• 4-Hydroxytamoxifen: Technical Use in Cancer and Cardiac Rese

  2026-06-14

  4-Hydroxytamoxifen (SKU B6167) addresses solubility and reproducibility challenges in breast cancer, prostate cancer, and cardiac myocyte research by providing a high-purity, DMSO-soluble estrogen receptor modulator. It should not be used in protocols requiring ethanol or aqueous solubility, and strict storage and handling are critical for maintaining reagent quality.

• CX-4945 (Silmitasertib): Reliable CK2 Inhibition for Cell As

  2026-06-13

  This article provides bench-level guidance for using CX-4945 (Silmitasertib, SKU A8330) in cell viability, cytotoxicity, and proliferation assays. Drawing on recent mechanistic studies and quantitative data, it addresses common lab challenges and compares CX-4945's advantages in reproducibility, selectivity, and workflow safety—enabling robust experimental outcomes for cancer and virology research.

• CCK-8 Induces Opioid-Dependent Anxiolytic Effects in Morphin

  2026-06-12

  This study demonstrates that cholecystokinin octapeptide (CCK-8) exerts anxiolytic effects in morphine-withdrawn rats by upregulating endogenous opioid activity via the CCK1 receptor. These findings clarify the neural interactions underlying affective symptoms of opioid withdrawal and suggest central CCK1 receptors as potential therapeutic targets.

• Fenofibrate as a Strategic PPARα Agonist: Beyond Liver Enlar

  2026-06-12

  Discover how Fenofibrate, a potent PPARα agonist, uniquely advances lipid metabolism and cancer biology research. This article dives deeply into mechanistic insights and assay strategies, offering practical guidance not found in prior reviews.

• AM251: Potent CB1 Receptor Antagonist for Cannabinoid Resear

  2026-06-11

  AM251 is a nanomolar-potency CB1 receptor antagonist widely used in cannabinoid receptor research. It modulates neurotransmitter release and neuronal excitability, making it a valuable tool for investigating endocannabinoid signaling and metabolic disorders. This article details AM251’s molecular action, evidence base, protocol parameters, and application boundaries.

• SEMA3E Drives Beige Adipocyte Differentiation via β-Catenin

  2026-06-11

  This study uncovers SEMA3E as a key regulator of beige adipocyte differentiation and thermogenesis in mice, acting through β-catenin signaling. The findings provide a mechanistic basis for targeting SEMA3E in metabolic disease research and shed light on the pathways underlying adipocyte plasticity.

• TPPU as a Next-Generation sEH Inhibitor: Redefining Lipid Si

  2026-06-10

  Explore how TPPU, a potent soluble epoxide hydrolase inhibitor, uniquely enables advanced research into epoxyeicosatrienoic acids metabolism and chronic inflammation. This article provides deep mechanistic insights and practical guidance for integrating TPPU into complex models, with a focus on lipid signaling and the liver-bone axis.

16332 records 1/1089 page Next 12345 下5页 Last page